 Scott Davis on Aug 17th, 2018 // No Comments
Arbutus Biopharma Corp (NASDAQ:ABUS) â€“ Research analysts at B. Riley raised their Q3 2018 earnings per share estimates for shares of Arbutus Biopharma in a research report issued on Monday, August 13th. B. Riley analyst M. Kumar now expects that the biopharmaceutical company will earn ($0.45) per share for the quarter, up from their previous estimate of ($0.46). B. Riley has a "Neutral" rating and a $11.50 price objective on the stock. B. Riley also issued estimates for Arbutus Biopharma's Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($0.33) EPS, FY2019 earnings at ($1.34) EPS, FY2020 earnings at ($1.20) EPS, FY2021 earnings at ($0.96) EPS and FY2022 earnings at ($0.85) EPS. Get Arbutus Biopharma alerts:
Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.09). Arbutus Biopharma had a negative net margin of 515.00% and a negative return on equity of 75.07%. The company had revenue of $1.20 million during the quarter. Several other equities research analysts have also weighed in on ABUS. Wedbush upped their price objective on Arbutus Biopharma from $6.00 to $7.00 and gave the company a "hold" rating in a research note on Monday. Zacks Investment Research lowered Arbutus Biopharma from a "hold" rating to a "sell" rating in a research note on Wednesday, August 8th. Chardan Capital reissued a "buy" rating and issued a $11.00 target price on shares of Arbutus Biopharma in a report on Monday, July 16th. BidaskClub raised Arbutus Biopharma from a "buy" rating to a "strong-buy" rating in a report on Thursday, June 21st. Finally, ValuEngine raised Arbutus Biopharma from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of "Buy" and an average target price of $9.58.
ABUS stock opened at $9.10 on Wednesday. Arbutus Biopharma has a 1-year low of $3.45 and a 1-year high of $12.60. The company has a market capitalization of $523.57 million, a PE ratio of -5.07 and a beta of 1.17. The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.67 and a current ratio of 13.67.
Several institutional investors and hedge funds have recently made changes to their positions in ABUS. DekaBank Deutsche Girozentrale acquired a new position in shares of Arbutus Biopharma in the 1st quarter worth approximately $174,000. Two Sigma Investments LP acquired a new position in Arbutus Biopharma during the 4th quarter worth $215,000. Rhumbline Advisers acquired a new position in Arbutus Biopharma during the 2nd quarter worth $243,000. Algert Global LLC acquired a new position in Arbutus Biopharma during the 2nd quarter worth $254,000. Finally, Goldman Sachs Group Inc. acquired a new position in Arbutus Biopharma during the 4th quarter worth $275,000. 33.64% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Michael J. Sofia sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $8.20, for a total value of $164,000.00. Following the transaction, the insider now directly owns 1,543,403 shares of the company's stock, valued at approximately $12,655,904.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, insider Michael J. Sofia sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, July 3rd. The stock was sold at an average price of $8.00, for a total value of $80,000.00. Following the completion of the transaction, the insider now directly owns 1,543,403 shares in the company, valued at $12,347,224. The disclosure for this sale can be found here . Insiders sold a total of 54,250 shares of company stock worth $473,518 over the last three months. 7.60% of the stock is owned by company insiders.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Read More: NASDAQ Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter 